Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date: October 25, 2024
Context: The filing discloses the presentation of clinical data at the 2024 American Society of Nephrology (ASN) Kidney Week regarding the Company's investigational agent, DISC-0974.
Key Financial Metrics
This Form 8-K is a current report focused on clinical trial updates and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The Company reported positive interim data from the Phase 1b clinical trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. Key findings from the single ascending dose (SAD) cohorts include:
- Hepcidin Reduction: Substantial, durable, dose-dependent reduction compared to placebo, with a median reduction greater than 75% from baseline at the highest dose level.
- Transferrin Saturation: Meaningful and sustained increase compared to placebo, with a median increase up to 3x from baseline at the highest dose level.
- Reticulocyte Hemoglobin: Early and sustained increase across all dose groups through Day 22. Maximal mean values were +1.14 pg (28 mg), +1.49 pg (40 mg), and +1.53 pg (60 mg) versus +0.21 pg on placebo.
- Hemoglobin Increase: Mean increases over the study period were +0.35 g/dL (28 mg), +0.54 g/dL (40 mg), and +0.55 g/dL (60 mg) compared to placebo. Maximal mean increases were +0.8 g/dL (40 mg) and +0.7 g/dL (60 mg).
- Individual Response: Maximal observed individual hemoglobin increases reached up to +1.8 g/dL at the 60 mg dose.
- Safety: DISC-0974 demonstrated acceptable safety and tolerability. Most adverse events were not related to the drug; treatment-related events were Grade 1 or 2.
Outlook, Risks, and Management Commentary
Outlook: Dose escalation in the SAD portion of the trial is ongoing.
Risks and Contingencies: DISC-0974 remains an investigational agent and is not approved for therapeutic use in any jurisdiction worldwide. The Company explicitly states it undertakes no obligation to update, supplement, or amend the material furnished in this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for complete data tables and methodology.
- Confirm the timeline for the next phase of the clinical trial or subsequent data readouts.
- Review the Company's most recent 10-Q or 10-K filing for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor regulatory communications regarding the safety profile of DISC-0974 as dose escalation continues.